Revvity Q1 revenue rises 2% to $665 million; adjusted EPS $1.01; revenue guidance raised
Revvity reported first-quarter 2025 revenue of $665 million, up from $650 million a year earlier, and GAAP EPS of $0.35 versus $0.21. Adjusted EPS from continuing operations was $1.01 versus $0.98. The company raised its full-year 2025 revenue guidance to $2.83-$2.87 billion, citing currency changes, and reaffirmed its organic growth and adjusted EPS guidance.
Key points
- Q1 2025 revenue of $665 million, up 2% reported and 4% organic, versus $650 million a year earlier.
- GAAP EPS of $0.35 versus $0.21; adjusted EPS from continuing operations of $1.01 versus $0.98.
- Full-year 2025 revenue guidance raised to $2.83-$2.87 billion; organic growth guidance of 3-5% and adjusted EPS guidance of $4.90-$5.00 reaffirmed.
- Diagnostics adjusted operating margin fell to 22.8% from 24.3%, while Life Sciences margin rose to 31.1% from 30.0%.
The filing
Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 28, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.